Davies, Faith
Rifkin, Robert
Costello, Caitlin
Morgan, Gareth
Usmani, Saad
Abonour, Rafat
Palumbo, Antonio
Romanus, Dorothy
Hajek, Roman
Terpos, Evangelos
Cherepanov, Dasha
Stull, Dawn Marie
Huang, Hui
Leleu, Xavier
Berdeja, Jesus
Lee, Hans C.
Weisel, Katja
Thompson, Michael
Boccadoro, Mario
Zonder, Jeffrey
Cook, Gordon
Puig, Noemi
Vela-Ojeda, Jorge
Farrelly, Eileen
Raju, Aditya
Blazer, Marlo
Chari, Ajai
Article History
Received: 8 January 2021
Accepted: 22 March 2021
First Online: 10 May 2021
Declarations
:
: This study was approved by the Advarra Institutional Review Board.
: FD reports honoraria from Adaptive, Celgene Corporation, Janssen, Oncopeptide, Roche, Sanofi, and Takeda; consultancy or research funding from Celgene Corporation, Janssen, Oncopeptide, Roche, Sanofi, and Takeda. RR is a current equity holder in McKesson; advisory board member for Takeda, Amgen, and BMS (Celgene); investigator for AbbVie; and consultancy for Takeda, Amgen, Celgene, BMS, Mylan, Coherus, BioSciences, and Fresenius. CC receives grants and honorarium from Takeda and BMS and honorarium from Karyopharm and Oncopeptides. GM has received funding from Celgene, BMS, Sanofi, Karyopharm, Janssen, Roche, and Genentech. SU receives research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; SU receives consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, and Takeda; SU receives speaking fees from Celgene, Janssen, Sanofi, and Takeda. RA reports grants from Takeda. AP is an employee of GSK. DC, DMS, HH, and DR are or were all employees of Millennium Pharmaceuticals, Inc., a wholly own subsidiary of Takeda Pharmaceutical Company Limited, at the time this research was conducted. RH receives consulting honoraria and/or research support received from Takeda, Novartis, Celgene, PharmaMar, Oncopeptides, Janssen, Amgen, AbbVie, and Bristol-Myers Squibb. ET declares honoraria from Amgen, BMS, Janssen, Celgene, Takeda, Genesis Pharma, and Sanofi and research funding from Janssen, Amgen, Sanofi, Takeda, and Genesis Pharma. XL receives honoraria from Takeda, Janssen, BMS, Sanofi, Magen, Oncopeptide, Karyopharm, Novartis, and Merck. JB receives research funding from Abbvie, Amgen, Acetylon, Bluebird, BMS, Celgene, Celularity, Constellation, CRISP Therapeutics, CURIS, EMD Sorono, Genentech, Glenmark, Ichnos, Janssen, Kesios, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, Vivolux. JB receives consultancy payments from Amgen, BioClinica, Bluebird, BMS, Celgene, CRISPR Therapeutics, Janssen, Karyopharm, Kite Pharma, Legend, Prothena, SecuraBio, and Servier. HCL reports consulting or advisory role for Takeda, Celgene, Adaptive Biotechnologies, Amgen, GSK, Sanofi, and Janssen; research funding from Takeda, Amgen, Daiichi Sankyo, Janssen, Celgene and GSK. KW reports grants from Amgen, Celgene, Sanofi, Janssen (all to the institution), honoraria and advisory board from Amgen, BMS, Celgene, Adaptive Biotech, Janssen, GSK, Karyopharm, Roche, Sanofi, Takeda, and Oncopeptides. MT is an advisor/consultant for Adaptive, BMS, Doximity, Elsevier, GRAIL/Ilumina, Syapse Precision Medicine Council, Takeda, and UpToDate. He receives research funding from AbbVie, Amgen, BMS, CRAB CTC, Denovo, GSK, Hoosier Research Network, Janssen, Lilly, LynxBio, Strata Oncology, Takeda, and TG Therapeutics. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GSK; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. JAZ reports consultancy or advisory role for Celgene, BMS, Prothena, Janssen, Amgen, Takeda, Caelum Biosciences, Intellia Therapeutics, Alnylam and Oncotherapeutics; institutional research funding from Celgene and BMS. GC receives grant/research support from Celgene/BMS, Janssen, and Takeda and honoraria from Amgen, BMS, Celgene, Janssen, Takeda, Roche, GSK, Oncopeptides, and Sanofi. NP reports consulting or advisory role for Takeda, Amgen, Celgene, and Janssen; speaker’s bureau for Celgene; honoraria from Takeda, Amgen, Celgene, Janssen, and The Binding Site; travel, accommodation, expenses and research funding from Celgene, Janssen, Amgen, and Takeda. EF, AR, and MB are or were employees of Xcenda, LLC at the time research was conducted; AC reports grants and personal fees from Janssen, grants and personal fees from Celgene, grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Amgen, personal fees from Bristol Myers Squibb, grants from Pharmacyclics, personal fees from Karyopharm, personal fees from Sanofi, grants and personal fees from Seattle Genetics, personal fees from Oncopeptides, grants and personal fees from Millenium/Takeda, personal fees from Antengene, personal fees from GlaxoSmithKline, and personal fees from Secura Bio. No further conflicts are reported by the authors.